7554-79-2

Usage

InChI:InChI=1/C9H7Cl2NO3/c10-5-1-2-6(7(11)3-5)9(15)12-4-8(13)14/h1-3H,4H2,(H,12,15)(H,13,14)

Upstream product

• 50-84-0 2,4 dichlorobenzoic acid 
• 89-75-8 2,4-dichlorobenzoyl chloride 
• 56-40-6 glycine 

Downstream Products

• 16352-86-6 2-(2,4-Dichlor-phenyl)-4-piperonyliden-oxazolinon-(5) 
• 16352-82-2 4-(2-chloro-benzylidene)-2-(2,4-dichloro-phenyl)-4H-oxazol-5-one 
• 16352-81-1 4-benzylidene-2-(2,4-dichloro-phenyl)-4H-oxazol-5-one 
• 132311-60-5 2,4-Dichloro-N-phenylcarbamoylmethyl-benzamide 
• 132311-62-7 2,4-Dichloro-N-[(4-phenoxy-phenylcarbamoyl)-methyl]-benzamide 
• 896742-21-5 (4Z)-2-(2,4-dichlorophenyl)-4-(2-furylmethylene)oxazol-5-one 
• 132311-61-6 2,4-Dichloro-N-(p-tolylcarbamoyl-methyl)-benzamide 
• 16352-85-5 2-(2,4-dichloro-phenyl)-4-(4-dimethylamino-benzylidene)-4H-oxazol-5-one 
• 16352-87-7 2-(2,4-dichloro-phenyl)-4-(3-phenyl-allylidene)-4H-oxazol-5-one 
• 16352-84-4 2-(2,4-dichloro-phenyl)-4-(3,4-dimethoxy-benzylidene)-4H-oxazol-5-one 
• 16352-88-8 2-(2,4-Dichlor-phenyl)-4-furfuryliden-oxazolinon-5 

Relevant academic research and scientific papers

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone-dipeptide scaffold

The preparation and structure-activity relationships (SARs) of potent and selective small molecule inhibitors of bacterial methionyl-tRNA synthetase (MetRS) derived from an oxazolone-dipeptide scaffold are described. Examples combine Staphylococcus aureus MetRS (SaMetRS) potency with selectivity over human MetRS. As a result of the SAR expansion compound 14a was identified, as a potent SaMetRS inhibitor (IC50=18 nM) having moderate inhibition of MetRS derived from Enterococci faecalis (IC50=3.51 μM).